SAN DIEGO –
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company
developing novel anti-infectives including immunotherapies, today
announced that the company will present new data highlighting its
Cloudbreak™ immunotherapy discovery platform and new antiviral program
at the upcoming World Antimicrobial Resistance (AMR) Congress taking
place October 25-26, 2018 in Washington, DC. The presentation, titled
“Immunobiotics: Cloudbreak Antibody Drug Conjugates (ADC) as
countermeasures against multi-drug resistant bacterial infections,” is
scheduled for 11:10 a.m. Eastern Time on Friday, October 26.
As the leading conference on antimicrobial resistance, the World
Antimicrobial Resistance Congress convenes over 400 stakeholders to
discuss critical challenges and opportunities to advance antibiotic and
diagnostics development, improve antimicrobial stewardship practice and
incentivize funding and partnering to bring innovation to patients and
the healthcare system in need. More information about the 2018 World
Antimicrobial Congress can be found at: http://www.terrapinn.com/conference/antimicrobial-resistance-congress-usa/index.stm
About Cloudbreak
The Cloudbreak immunotherapy platform is a fundamentally new approach
for the treatment of infectious disease that, in a single molecule,
pairs potent antimicrobials with agents that redirect the immune system
to destroy fungal, bacterial and viral pathogens. Cidara is initially
developing Cloudbreak candidates for the treatment and prevention of
serious multi-drug resistant (MDR) Gram-negative bacterial infections
and viral infections. Different from traditional antibiotics or
antivirals, the Cloudbreak ADCs physically link the pathogen and the
immune component to eradicate or prevent pathogens via dual killing
mechanisms.
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on developing
new anti-infectives that have the potential to transform the standard of
care and save or improve patients’ lives. The company is currently
advancing its novel echinocandin antifungal, rezafungin acetate, in a
Phase 3 clinical trial in the treatment of candidemia and invasive
candidiasis and plans to initiate a second Phase 3 trial in the
prophylaxis of invasive fungal infections. Rezafungin has improved
pharmacokinetics compared to existing echinocandins and the potential
for expanded utility across patient settings. It is the only once-weekly
product candidate in development for the treatment and prevention of
life-threatening invasive fungal infections. Cidara also is leveraging
its novel Cloudbreak™ platform to develop antibody-drug conjugates for
the treatment of serious viral and Gram-negative bacterial infections.
Cloudbreak is the first immunotherapy discovery platform designed
specifically to create compounds that directly kill pathogens and also
direct a patient’s immune cells to attack and eliminate bacterial,
fungal or viral pathogens. Cidara is headquartered in San Diego,
California. For more information, please visit www.cidara.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are
not historical facts are “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not limited
to, statements regarding the potential for the Cloudbreak immunotherapy
platform to treat and prevent serious multi-drug resistant Gram-negative
bacterial infections and viral infections and to fundamentally change
the treatment of infectious diseases. Risks that contribute to the
uncertain nature of the forward-looking statements include: the success
and timing of Cidara’s preclinical studies and clinical trials;
regulatory developments in the United States and foreign countries;
changes in Cidara’s plans to develop and commercialize its product
candidates; Cidara’s ability to obtain additional financing; Cidara’s
ability to obtain and maintain intellectual property protection for its
product candidates; and the loss of key scientific or management
personnel. These and other risks and uncertainties are described more
fully in Cidara’s Form 10-Q most recently filed with the United States
Securities and Exchange Commission. All forward-looking statements
contained in this press release speak only as of the date on which they
were made. Cidara undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the date on
which they were made.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181024005127/en/
INVESTOR CONTACT:
Westwicke Partners, LLC
Robert H.
Uhl, 858-356-5932
Managing Director
robert.uhl@westwicke.com
or
MEDIA
CONTACT:
Sam Brown Inc.
Christy Curran, 615-414-8668
ChristyCurran@sambrown.com
